Biocon Biologics's Shreehas Tambe Speaks On Us Fda's Observation | Bazaar Open Exchange | Cnbc-Tv18

Biocon Biologics's Shreehas Tambe Speaks On US FDA's Observation | Bazaar Open Exchange | CNBC-TV18

Biocon Biologics' Shreehas Tambe Speaks On The Firm's Deal With Japan's Yoshindo | CNBC-TV18

Confident That Issues At Malaysian Plant Will Be Behind Once It Is Inspected: Biocon Biologics

Biocon: US FDA Completes Inspection At Mfg Unit In Bengaluru With No Observation

Biocon Biologics is well-placed to take advantage of opportunities in the biosimilars space: CEO

CNBC International News

Biocon Shares Fall After Malaysia Unit Receives 8 Observations From US FDA | CNBC TV18

Biocon: US FDA Inspection Of Bengaluru Facility A Routine Review

Biocon Surges After The US FDA Issues A VAI Status To Its Biologics Unit In Bengaluru | CNBC TV18

Biocon Biologics Names Shreehas Tambe as New MD, CEO

Medical Dialogues

Shreehas Tambe CEO & MD Biocon Biologics on 'ET Now ON THE GO'

Biocon Biologics

Kiran Mazumdar Shaw Shares Her Views On Biocon Biologics Acquiring Viatris Biosimilar's Business

LIVE | HMPV Virus: Do You Need To Worry? | N18L | CNBC TV18

Insulin Aspart & Bevacizumab Have Seen Approvals Across Markets Globally: Biocon Biologics

Brands Wil Be Exclusive To Eris, Co Will Have Right To Commercialise These Brands: Biocon Biologics

BiosimilarWorkshop | Mr. Shreehas Tambe revealed the secret sauce behind Biocon’s success

Biologics Workshop

Biocon Sells 5.4% Stake In Syngene To Fund Viatris Biologics Biz Acquisition | Halftime Report

Biocon Biologics Meets The Billion Dollar Commitment: Shreehas Tambe, CEO & MD, Biocon Biologics

Biocon Biologics Reports Weak Q1 Numbers, With Margin Contracting QoQ | CNBC TV18

Biocon Gets US FDA Adequacy Letter For gLiraglutide API | CNBC TV18